Access to biologics and Janus kinase inhibitors for treatment of rheumatic diseases in the biosimilars era in Poland: a nation-level study

Abstract

INTROduCTION By reducing treatment costs, biosimilars provide an opportunity to improve accessibility to highly effective drugs. ObjECTIvEs This study aimed to evaluate access to biologic disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKis) among patients with rheumatic musculoskeletal diseases within a 10 year timeframe in Poland. PATIENTs ANd mEThOds We performed a retrospective analysis using a nationwide public payer database. REsuLTs By 2022, 11102, 6602, and 4400 patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) were treated with bDMARDs or JAKis. Peak drug utilization was observed for adalimumab, followed by etanercept and tocilizumab. Within the study timeframe, the estimated access to innovative drugs increased from 0.8%, 1.4%, and 0.8% to 3.2%, 8.7%, and 3.5% for RA, PsA, and axSpA patients, respectively. Affordable tumor necrosis factor inhibitors (TNFis) still predominate among innovative therapeutics, but their market share declined from 87% to 46%. The number of patients treated with other bDMARDs/JAKis almost doubled within the prespecified timeframe. Overall, the average annual treatment cost per patient decreased by 60%, from 7315 EUR to 2886 EUR. Despite recent safety warnings, JAKis appear to be increasingly utilized. Additional analyses regarding the COVID-19 pandemic showed impaired access to intravenous therapies, but not subcutaneous or oral formulations. CONCLusIONs In Poland, biosimilars-related savings improved availability of higher-priced innovative drugs rather than less costly TNFis. Data-driven resource allocation and dedicated policy solutions facilitating access to affordable biologics are recommended.